Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Developing User Personas to Aid in the Design of a User-Centered Natural Product-Drug Interaction Information Resource for Researchers.

Boyce RD, Ragueneau-Majlessi I, Yu J, Tay-Sontheimer J, Kinsella C, Chou E, Brochhausen M, Judkins J, Gufford BT, Pinkleton BE, Cooney R, Paine MF, McCune JS.

AMIA Annu Symp Proc. 2018 Dec 5;2018:279-287. eCollection 2018.

2.

Drug-Drug Interactions of Infectious Disease Treatments in Low-Income Countries: A Neglected Topic?

McFeely SJ, Yu J, Zhao P, Hershenson S, Kern S, Ragueneau-Majlessi I, Hartman D.

Clin Pharmacol Ther. 2019 Jun;105(6):1378-1385. doi: 10.1002/cpt.1397. Epub 2019 Mar 21.

3.

Identification and Evaluation of Clinical Substrates of Organic Anion Transporting Polypeptides 1B1 and 1B3.

McFeely SJ, Ritchie TK, Yu J, Nordmark A, Levy RH, Ragueneau-Majlessi I.

Clin Transl Sci. 2019 Jul;12(4):379-387. doi: 10.1111/cts.12623. Epub 2019 Mar 12.

4.

Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017.

Yu J, Petrie ID, Levy RH, Ragueneau-Majlessi I.

Drug Metab Dispos. 2019 Feb;47(2):135-144. doi: 10.1124/dmd.118.084905. Epub 2018 Nov 15. Review.

PMID:
30442649
5.

Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016.

Yu J, Zhou Z, Tay-Sontheimer J, Levy RH, Ragueneau-Majlessi I.

Drug Metab Dispos. 2018 Jun;46(6):835-845. doi: 10.1124/dmd.117.078691. Epub 2018 Mar 23.

PMID:
29572333
6.

Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Preclinical and Clinical Findings.

Yu J, Zhou Z, Tay-Sontheimer J, Levy RH, Ragueneau-Majlessi I.

J Pharm Sci. 2017 Sep;106(9):2312-2325. doi: 10.1016/j.xphs.2017.04.004. Epub 2017 Apr 13. Review.

PMID:
28414144
7.

What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the US FDA in 2015.

Yu J, Zhou Z, Owens KH, Ritchie TK, Ragueneau-Majlessi I.

Drug Metab Dispos. 2017 Jan;45(1):86-108. Epub 2016 Nov 7. Review.

PMID:
27821435
8.

Key Findings from Preclinical and Clinical Drug Interaction Studies Presented in New Drug and Biological License Applications Approved by the Food and Drug Administration in 2014.

Yu J, Ritchie TK, Zhou Z, Ragueneau-Majlessi I.

Drug Metab Dispos. 2016 Jan;44(1):83-101. doi: 10.1124/dmd.115.066720. Epub 2015 Sep 30. Review.

PMID:
26424199
9.

Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.

Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N.

Drug Metab Dispos. 2015 Nov;43(11):1823-37. doi: 10.1124/dmd.115.065920. Epub 2015 Aug 21. Review.

10.

Drug disposition and drug-drug interaction data in 2013 FDA new drug applications: a systematic review.

Yu J, Ritchie TK, Mulgaonkar A, Ragueneau-Majlessi I.

Drug Metab Dispos. 2014 Dec;42(12):1991-2001. doi: 10.1124/dmd.114.060392. Epub 2014 Sep 30. Review.

PMID:
25271211
11.

Microplate-based platform for combined chromatin and DNA methylation immunoprecipitation assays.

Yu J, Feng Q, Ruan Y, Komers R, Kiviat N, Bomsztyk K.

BMC Mol Biol. 2011 Nov 18;12:49. doi: 10.1186/1471-2199-12-49.

Supplemental Content

Loading ...
Support Center